ICPM 2022: Scientists call for cooperative participation of all partners & patients in R&D of new drugs

The scientists of the 20th International Congress of Pharmaceutical Medicine – ICPM 2022 called for cooperative participation of all partners with equal contribution of patients in the research and development of new drugs.

The 20th International Conference of Pharmaceutical Medicine (20th ICPM 2022), a leading international scientific conference of biomedicine, pharmaceutical research and technology that took place in Athens, at the Stavros Niarchos Foundation Cultural Center from October 19th to 21st. The 20th ICPM was co-organized by the Hellenic Society of Pharmaceutical Medicine- EL.E.F.I. and the International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine – IFAPP.
The conference successfully met its goal of highlighting the exponentially beneficial accomplishments of biomedical research and development of advanced medical treatments and technologies, as well as a view to a near future horizon.
In the realization of this goal, 104 distinguished scientists, high ranking academic researchers, prestigious experts from regulatory authorities, and leaders of the international biopharmaceutical community, who participated as speakers and chairs, contributed significantly on what lies ahead in pharmaceutical medicine.
In parallel, young and rising biomedical researchers were given the opportunity to present ongoing research activities, with major announcements, on modern genomic tools, newer pharmacological models and medical devices.
The hybrid ICPM 2022 was actively attended by 207 pharmaceutical medicine specialists of the international R&D research ecosystem, either in person or online.
State-of-the-art research methodologies, new clinical trial designs, as well as therapeutic innovations that will improve clinical practice through Real World
Data – Real World Evidence (RWD-RWE) were presented, in connection with evolving topics in Data Science and Research Governance. The rich and diverse program of the Conference (www.icpm2022.gr) included lectures, round tables, dialogues, and workshops, with an emphasis on biomedical R&D for public health and cutting-edge issues in paediatric research and pharmaceutical medicine education.
The physical presence and active participation of most of the delegates and faculty from 27 countries and 5 continents, as well as the large online audience, fueled a diverse dialogue in the co-shaping of new trends.
Developments and the future of biomedical, biotechnological research, therapeutics and medtech digital innovation were discussed with representatives of patient associations—main partners in the patient-centered mission of science and research.
The benefits of organizing the conference in Greece were multiple, as stated by the President of the Conference Varvara Baroutsou:

The organization of ICPM 2022 highlighted the outstanding performance and scientific potential in pharmaceutical medicine by promoting new collaborations with the international research and development (R&D) ecosystem in the field of basic – translational – clinical research and bioethics.

The 20th ICPM 2022 international conference of IFAPP & EL.E.F.I. created a climate of mutual understanding between scientists and experts from academia, regulatory bodies, research institutions and strengthened collective thinking around the challenges and imperative solutions for the successful implementation of the new European Regulation on Clinical Trials (EU- CTR) in Europe, Greece and internationally.
The keynote speeches of the international conference were delivered by Prof. Achilleas Gravanis on the subject of “The Post-Covid Era of Drug Development”, which covered the new technologies for the development of effective antiviral and multivalent vaccines against other viruses besides SARS-CoV-2 and therapeutic mRNA vaccines in non-infectious diseases, and by Prof. Nektarios Tavernarakis, on the subject “Development of Novel Genetic Tools in Biomedical Research”, who reviewed the research progress in the modern era with the rapid integration of new genetic technologies and their potential applications, as well as the particularities of the prudent management of gene editing tools.
Many distinguished academics, expert scientists, bioethics committee members and representatives of the biopharmaceutical and medtech industry and patient associations, from all over the world, delivered high interest talks on cutting-edge topics.
In the session “Patient and Public Involvement (PPI) in Medicines R&D: Let us walk the Talk”, Professor Christoph Meier from the University of Zurich and Jan Geissler, representative of Patient Padvocates from Germany, emphasized the importance of patient reported outcomes and patient preferences in the configuration of the research goals of drugs under development but also in their clinical application.
In the roundtable “Current situation and issues with the Data driven Research in US”, Dr Laura Biven, from the US National Institute of Health, referred to the developing Data Science in its interdisciplinary dimension, and in particular to ensuring the equity and diversity of patient data with the application of artificial intelligence, while ensuring the integrity, reliability and integrity of the data.
The dialogue on the revision of the Declaration of Helsinki, a fundamental principle for biomedical research for the protection of the rights of people participating in clinical research, with the introduction of the framework and process of the 8th revision proposal by Jack Resneck, President of American Medicine, had an exceptional impact. The commentary by Dr Otmar Kloiber, Secretary General of the World Medical Association, for the inclusion of recent developments since its last renewal in 2013, by applying the principles of the Declaration of Helsinki in the changing landscape of the social environment & new technologies -AI, new clinical trials adaptive designs, virtual trials, data science and secondary data use.

Dr. Varvara Baroutsou summarized the three-day conference conclusions by highlighting the contribution of the 20th ICPM 2022 to the need for more substantial patient-centered innovation, more transparency, stronger documentation for more targeted, safer and efficient therapeutic solutions through collaborative participation of partners and equal contribution of patients in research and development.
The conference was attended by the heads of international regulatory organisations such as the European Medicines Agency (EMA), the Medicines and Healthcare Products Regulatory Authority (MHRA-UK), the European Network for Health Technology Assessment (EUnetHTA), the US National Institutes of Health (NIH, USA), representatives of international scientific organizations such as the Council of International Organizations of Medical Sciences (CIOMS), WHO-UNESCO.

The conference was held under the auspices of the Ministry of Development and Investments as well as of public research institutions, medical societies and organisations: Foundation for Technology and Research (ΙΤΕ / FORTH), National Center for Research and Technological Development (EKETA / CERTH), Medical Association of Athens, Medical Society of Athens, Hellenic Pasteur Institute, EUCROF & HACRO.
The conference was welcomed by the Deputy Minister of Health Dr. Mina Gaga, the Rector of EKPA Prof. Meletios Dimopoulos, Dr. Lembit Rägo, Secretary General of the Council of International Organizations of Medical Sciences (CIOMS), and Dr. Steffen Thirstrup, Chief Physician of the European Medicines Agency (EMA), as well as statutory bodies of the pharmaceutical industry, who underlined the value of the conference regarding research, development and clinical trials for the better health of citizens in Greece, Europe and the world.
With the end of the 20th ICPM 2022, the term of Varvara Baroutsou as President of the International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine (IFAPP) began.

619x417px_ICPM_Web banner_Final Programme

ICPM 2022 Programme is published

The 20th International Conference on Pharmaceutical Medicine – ICPM, the reknown event on biomedical science, pharmaceutical research and technology starts next week, on October 19th until the 21st, in Athens and virtually.

View the final scientific programme here:


Looking forward to seeing you in Athens for a unique learning journey and enlighten your professional perspective on what lies ahead in Pharmaceutical Medicine.



1st announcement

The Greek Society of Pharmaceutical Medicine (ELEFI) and the International Federation of Pharmaceutical Physicians and Pharmaceutical Medicine (IFAPP) invite you to the international congress

20th International Conference on Pharmaceutical Medicine-ICPM 2022

“What lies ahead in Pharmaceutical Medicine”

in Athens, Greece, next October, 19th-21st, 2022.

At a critical moment for the evolution of the pandemic, with optimism stemming from intensification of vaccination against SARS-CoV2


are planning to deliver #ICPM 2022: an exceptional hybrid educational experience.

The COVID-19 pandemic is likely to impact educational activities in 2022 and, as many of our guest speakers from Greece and abroad may face difficulties travelling to an in-person conference, we have already included the opportunity for online participation of congress faculty members and attendees.

We are aiming to cover all the latest developments in modern Pharmaceutical Medicine and will host dedicated Biomedical Research sessions. Additionally, we will focus on New Technology Platforms, Precision Medicine, Advanced Clinical Medicine, Career Development and Professional Competencies in Pharmaceutical Medicine.

We are optimistic that the digital and onsite format of the congress will provide opportunities for networking and interaction with our members, the academic community, researchers, clinical investigators, and other stakeholders and trigger lively discussions, either face-to-face (or “mask-to-mask”) or in online forums.


Call for Speakers

This call focuses on talks given by international experts that discuss Pharmaceutical Medicine & Science recent developments from a forward-thinking perspective. We invite you to submit an abstract for an ICPM2022 talk covering a topic including (but not limited to):

  • Lessons learned from COVID-19 crisis and approaches to sustainably ensure the Collaborative Biomedical of R&D in future.
  • Reflections on recent developments in Open Science & Artificial Intelligence Horizon.
  • Innovative and novel HTA models for emerging challenges with advanced cell &gene therapies, modern medical devices and digital health.
  • Best practices to exploit the potential of Open Science for Public Interest such as participation and information literacy.



Please submit your application as .pdf including an outline of your talk and the benefit for the conference (not more than 500 words) as well as title, CV (including talks as invited speaker), affiliation, and contact details. 

  • Please note that a submission of a talk with more than one speaker is not possible.
  • All submissions will be reviewed by the members of the Scientific Committee. Authors of accepted applications will be invited to give an on-line talk at the conference. Talks can be pre-recorded, but speakers are expected to be available for questions. The application and talk must be in English.
  • Please send your application as .pdf document at the Conference Secretariat, info@icpm2022.gr
  • Due date for submissions: June 10th, 2022